Abstract
OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.
| Original language | English (US) |
|---|---|
| Journal | Journal of Computer Assisted Tomography |
| DOIs | |
| State | Accepted/In press - Sep 27 2016 |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance. / Chu, Linda Chi Hang; Pozzessere, Chiara; Corona Villalobos, Celia; Castaños, Sandra; Rastegar, Neda; Halappa, Vivek; Bonekamp, Susanne; Emurano, Emi; Kamel, Ihab R.
In: Journal of Computer Assisted Tomography, 27.09.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance
AU - Chu, Linda Chi Hang
AU - Pozzessere, Chiara
AU - Corona Villalobos, Celia
AU - Castaños, Sandra
AU - Rastegar, Neda
AU - Halappa, Vivek
AU - Bonekamp, Susanne
AU - Emurano, Emi
AU - Kamel, Ihab R
PY - 2016/9/27
Y1 - 2016/9/27
N2 - OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.
AB - OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.
UR - http://www.scopus.com/inward/record.url?scp=84988924620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988924620&partnerID=8YFLogxK
U2 - 10.1097/RCT.0000000000000457
DO - 10.1097/RCT.0000000000000457
M3 - Article
C2 - 27680411
AN - SCOPUS:84988924620
JO - Journal of Computer Assisted Tomography
JF - Journal of Computer Assisted Tomography
SN - 0363-8715
ER -